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Effects of integrase inhibitor‑based 
antiretroviral therapy on brain 
outcomes according to time 
since acquisition of HIV‑1 infection
Anna Prats1,2,3,16, Ignacio Martínez‑Zalacaín4,5,16, Beatriz Mothe1,6,7, Eugènia Negredo1,7, 
Núria Pérez‑Álvarez1,8, Maite Garolera9,10, Sira Domènech‑Puigcerver11, Pep Coll1,12, 
Michael Meulbroek12, Anna Chamorro1, Carmina R. Fumaz1, Maria J. Ferrer1, 
Bonaventura Clotet1,6,7, Carles Soriano‑Mas4,13,14* & Jose A. Muñoz‑Moreno1,15*
Integrase strand transfer inhibitors (INSTI) are a main component of the current antiretroviral 
regimens recommended for treatment of HIV infection. However, little is known about the impact 
of INSTI on neurocognition and neuroimaging. We developed a prospective observational trial 
to evaluate the effects of INSTI‑based antiretroviral therapy on comprehensive brain outcomes 
(cognitive, functional, and imaging) according to the time since HIV‑1 acquisition. We recruited men 
living with HIV who initiated antiretroviral therapy with INSTI < 3 months since the estimated date 
of HIV‑1 acquisition (n = 12) and > 6 months since estimated date of HIV‑1 acquisition (n = 15). We 
also recruited a group of matched seronegative individuals (n = 15). Assessments were performed 
at baseline (before initiation of therapy in HIV arms) and at weeks 4 and 48. Baseline cognitive 
functioning was comparable between the arms. At week 48, we did not find cognitive differences 
between starting therapy with INSTI earlier than 3 months or later than 6 months after acquisition of 
HIV‑1 infection. Functional status was poorer in individuals diagnosed earlier. This effect recovered 
48 weeks after initiation of therapy. Regarding brain imaging, we found that men living with HIV 
initiating antiretroviral therapy later experienced a greater decrease in medial orbitofrontal cortex 
over time, with expected negative repercussions for decision‑making tasks.
Cognitive disorders are a common complication in people living with HIV (PLWH). HIV-associated neuro-
cognitive disorders (HAND) have been described in 30–50% of this population, despite the use of combina-
tion antiretroviral therapy (cART)1,2. The neuropathogenesis of HAND remains unclear, although it appears to 
be multifactorial. Early HIV-related events before initiation of antiretroviral therapy could induce irreversible 
damage to the central nervous system (CNS). Prompt initiation of cART could therefore prevent or mitigate 
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the effects of HIV on the  CNS3–5. This possibility is supported by recent data, which show attenuation of brain 
inflammatory processes after initiation of cART during acute or primary  infection6–9.
Integrase strand transfer inhibitors (INSTI) are currently part of the first-line cART regimens recommended 
for HIV  treatment10. However, their impact on the CNS remains controversial. Most of the studies investigating 
the CNS effects of INSTI have evaluated the potential appearance of neuropsychiatric symptoms, notably missing 
other crucial CNS dimensions, such as cognitive performance, functional outcomes, and brain  imaging11. One 
recent cross-sectional study provided information on the outcomes of cognitive and structural brain  imaging12. 
Importantly, the authors found poorer performance in the verbal learning and memory domain in PLWH on 
INSTI-based regimens compared with PLWH not taking INSTI and revealed smaller volumes in the frontal, 
brainstem, and cerebellar regions.
We developed a prospective observational trial to evaluate the impact of INSTI on comprehensive brain 
outcomes and investigated the association with time since acquisition of HIV-1. We recruited men living with 
HIV (MLWH) who started antiretroviral therapy with INSTI < 3 months after the estimated date of acquisition, 
MLWH who initiated therapy with INSTI > 6 months after the estimated date of acquisition, and a group of 
matched seronegative people.
Methods
Study participants and design. Thirty cART-naïve HIV-1-positive adult men were recruited at the HIV 
Clinical Unit of Germans Trias i Pujol University Hospital, Barcelona, Catalonia, Spain, from October 2015 to 
April 2017. The participants were ≥ 18 years old and were expected to initiate cART including INSTI. Therapy 
was initiated following clinical antiretroviral guidelines.
MLWH were divided into 2 groups according to the time since estimated date of HIV-1 acquisition. The first 
arm (early treatment arm) met the following criteria: recent or acute infection confirmed by (1) positive plasma 
viral load and/or presence of p24 antigen with a negative enzyme-linked immunosorbent assay (ELISA) result, or 
(2) positive ELISA result and undefined Western blot result, or (3) positive ELISA result and absence of antigen 
band p31 in a positive Western blot test, or (4) seroconversion according to ELISA in less than 3 months; and 
agreement to start cART in less than 90 days from the estimated date of acquisition of HIV-1. The second arm 
(later treatment arm) comprised participants with HIV who did not meet the criteria for the early treatment 
arm and whose estimated time since acquisition was longer than 6 months, as confirmed by viral load set-point 
criteria after 2 consecutive viral loads with a determination on the same logarithmic scale and agreement to 
start cART 6 months after the estimated date of acquisition. A control group matched for age, sex, and edu-
cational level with the HIV arms and comprising non-MLWH was recruited from a community health center. 
The exclusion criteria were age > 60 years, intellectual disability, current or past neurological disease, current or 
past CNS-related opportunistic infection, and current severe psychiatric disorder. MLWH who presented poor 
adherence (< 90%), interrupted cART, or ceased INSTI during follow-up were excluded from the study analyses. 
Study assessments were performed at baseline (i.e., before initiation of cART in HIV arms) and at weeks 4 and 
48 after initiation of cART.
All participants gave their informed consent before enrolment. The study was approved by the Research Ethics 
Committee of Germans Trias i Pujol University Hospital (FLS-ANT-2015–01) and was conducted in compliance 
with the Helsinki Declaration of 1964 (1996 revision) and Good Clinical Practice guidelines. The trial is registered 
at ClinicalTrials.gov (NCT03835546, date of registration: 08/02/2019).
Cognitive assessment. Participants underwent a comprehensive neuropsychological assessment of 6 
cognitive domains, with 2 measures per domain (Supplementary Table S1). A total of the 12 scores obtained 
made it possible to calculate a global cognitive measure, the neuropsychological z score (NPZ-12), which was 
based on the average of standardized z scores. Cognitive impairment was defined as performing ≥ 1 standard 
deviation below the normative mean in ≥ 2 of the cognitive domains assessed. Standardized z scores were always 
used for comparisons. Cognitive complaints were also recorded based on the European AIDS Clinical Society 
 guidelines13. HAND were determined based on the Frascati  criteria14.
Functional assessment. Functional outcomes included CNS adverse events, daily functioning, emotional 
status, and quality of life. CNS adverse events were assessed by an adapted inventory including adverse effects 
from the US Food and Drug Administration (FDA) for the different INSTI studied. Daily functioning was evalu-
ated using a version of the Instrumental Activities of Daily Living (IADL)  questionnaire15,16. Depressive and 
anxiety symptoms were recorded using the Hospital Anxiety and Depression Scale (HADS)17,18. The Perceived 
Stress Scale (PSS-10) was used for perceived  stress19,20. Quality of life was evaluated using an adapted version of 
the Medical Outcomes Study HIV Health Survey (MOS-HIV)  questionnaire21.
Brain imaging acquisition and preprocessing. Brain imaging data were collected using a 3 T magnetic 
resonance imaging scanner (Siemens Verio, Siemens Healthcare Sector, Erlangen, Germany) equipped with a 
32-phased-array head coil offered by the manufacturer. A high-resolution T1-weighted 3D structural image was 
acquired individually for each participant in the axial plane at the 3 study timepoints with the following param-
eters: 192 slices; repetition time = 1900 ms; echo time = 2.72 ms; flip angle = 9◦ ; field of view = 260 × 260 mm; 
matrix size = 256 × 256 pixels; in-plane resolution = 0.96 × 0.96   mm2; slice thickness = 0.9 mm. Data were pre-
processed executing technical computing software (MATLAB 7.14; The MathWorks, Natick, MA, USA) and 
statistical parametric mapping (SPM12; The Welcome Department of Imaging Neuroscience, London, UK). 
Images were examined by experienced members of the research team, mainly to rule out presence of artifacts or 
other effects that could interfere in data analyses. Subsequently, images were preprocessed using 2 independent 
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approaches performed in parallel. First, at the individual level, longitudinal preprocessing consisted of an initial 
rigid-body within-subject co-registration to the first scan to ensure good starting estimates. This was followed by 
a pairwise longitudinal registration of the scans for each participant to obtain an average image and a Jacobian 
difference  map22. The average image was then segmented, and the gray matter voxels were multiplied by the 
Jacobian difference map to obtain a gray matter volume change map for each  participant23. Next, we generated 
a specific template of our study sample in Montreal Neurological Institute (MNI) space using a Diffeomorphic 
Anatomical Registration Through Exponentiated Lie Algebra algorithm (DARTEL)24, which was used to spa-
tially normalize the gray matter volume change maps.
Data analyses. Data analyses were based on cross-sectional and prospective comparisons from baseline to 
week 4 and from baseline to week 48. Descriptive results were based on comparisons between the 3 study arms. 
Prospective results were based on 2-arm comparisons (early treatment arm vs the control arm; and later treat-
ment arm vs the control arm).
The primary study endpoint was change in neurocognitive performance from baseline to week 48 measured 
based on the NPZ-12 score. Secondary endpoints comprised the change in neurocognitive performance from 
baseline to week 4 measured based on the NPZ-12 score, as well as the change in specific cognitive scores, func-
tional outcomes, and structural brain imaging markers from baseline to week 4 and from baseline to week 48. 
Changes were compared between each HIV arm and the control group (2-arm comparisons).
Statistical tests were applied according to the type and distribution of variables and included the chi-square, 
Fisher, independent t, and ANOVA for mean tests. Longitudinal repeated-measures ANOVA was used for pro-
spective intra-group comparisons. Linear mixed models were applied to study the effect of unbalanced variables 
at baseline. All comparisons were univariate and 2-tailed. Statistical significance was set at p < 0.05. Effect sizes 
were also calculated to quantify the magnitude of the differences found using Cohen’s d. Values were considered 
small when scores were less than 0.20, medium when they ranged between 0.50 and 0.80, and large when they 
were over 0.80. Power calculations were performed for the primary study endpoint. With a power of 80%, the 
effect size cut-off was established at 0.55. Statistical analyses were performed using SPSS, version 15 (SPSS Inc, 
Chicago, Illinois, USA) and R, version 3.5.1 (https:// cran.r- proje ct. org).
Brain imaging data were analyzed with SPM12. For the longitudinal analyses, gray matter volume change 
maps were compared to detect areas of increase or decrease in volume across the different timepoints. Baseline 
gray matter images were also compared to detect putative voxel-wise volume differences at baseline across the 3 
arms. Gray matter images from each timepoint were used to extract the volumes of the regions of interest stem-
ming from previous analyses, which were further studied in SPSS. SPM12 analyses were thresholded at p < 0.05, 
and the family wise error (FWE) corrected for the number of independent comparisons.
Results
Characteristics of the study participants. A total of 45 participants were recruited, 15 per study arm. 
Three (6%) of those in the early treatment arm were excluded due to protocol failure: 2 because the estimated 
date since HIV-1 acquisition could not be established, and 1 because an intellectual disability was detected. One 
participant (2%) in the control arm was not included in the data analyses at week 4 because of loss to follow-up. 
Eight participants (19%) were excluded from the week-48 analyses: in the early treatment arm, 1 (2%) was lost 
to follow-up; in the later treatment arm, 2 (5%) interrupted cART voluntarily and 1 (2%) switched antiretroviral 
therapy due to a lipid-related issue; and in the control arm, 2 (5%) were lost to follow-up and 2 (5%) initiated 
pre-exposure prophylaxis (PrEP).
Regarding the characteristics of the sample, participants had a mean (standard deviation [SD]) age of 33 (10) 
years and a mean of 14 (3) years of education. We detected significant differences in days from diagnosis of HIV-1 
infection to initiation of cART (p = 0.028) and plasma viral load  log10 (p = 0.010). The remaining demographic 
and clinical variables were equivalent between the groups. INSTI were distributed as follows: dolutegravir, 12 
participants (44%); elvitegravir, 10 (37%); and raltegravir, 5 (19%) (p = 0.198). Table 1 shows the characteristics 
of the study sample.
Cognitive outcomes. At baseline, no significant differences were found between the 3 arms in frequency 
of cognitive complaints (p = 0.962), frequency of cognitive impairment (p = 0.202), and global cognitive score 
(NPZ-12) (p = 0.771) (Fig. 1A). Similarly, no differences were found between specific cognitive scores (Supple-
mentary Table S1). A worse NPZ-12 score was associated with a longer time since diagnosis of HIV-1 infection 
(p = 0.025) and a higher rate of potential comorbidities for cognitive impairment (p = 0.017).
Regarding the primary study endpoint, no differences were detected at week 48: early treatment arm, 0.08 
(0.26); later treatment arm, 0.31 (0.28); control arm, 0.25 (0.19) (p = 0.147) (Fig. 1B). Likewise, no differences 
were found previously at week 4 (mean [SD] change in NPZ-12): early treatment arm, 0.06 (0.20); later treatment 
arm, 0.14 (0.25); control arm, 0.11 (0.28); p = 0.724. Equivalent results were confirmed when linear mixed models 
were applied, taking into consideration unbalanced variables at baseline (i.e., days since HIV diagnosis to cART 
initiation and plasma viral load  log10). Changes in specific cognitive scores are shown in Supplementary Table S2.
Functional outcomes. At baseline, depressive (p = 0.032), anxiety (p = 0.044), and perceived stress 
(p = 0.042) symptoms were significantly higher in the early treatment arm. The remaining functional outcomes 
were comparable (Supplementary Table S3).
At week 4, a more marked change was observed in daily functioning in the early treatment arm than in the 
control arm: 1.25 (1.65) vs 0 (1.30); p = 0.047, d = 0.82 (Table 2). This change was not maintained at week 48. A 
significantly negative change was found in depression, anxiety, and perceived stress symptoms at week 48 in 
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Table 1.  Characteristics of the study sample. Values are expressed as mean (standard deviation) except when 
indicated otherwise. Continuous variables were compared using the ANOVA for means test. Categorical 
variables were compared using the chi-square test. Statistical significance was set at p < 0.05. Bold values denote 
statistical significance. Abbreviations: 3TC = lamivudine; ABC = abacavir; cART = combination antiretroviral 
therapy; DTG = dolutegravir; EVG = elvitegravir; FTC = emtricitabine; INSTI = integrase strand transfer 
inhibitor; TAF = tenofovir alafenamide fumarate; TDF = tenofovir disoproxil fumarate; RAL = raltegravir. 
a Detection limit of ≤ 40 copies/mL. b Based on the Frascati criteria (Antinori A, et al., Neurology, 2007), which 
refer to pre-existing conditions that may act as contributors in cognitive performance, mainly mild psychiatric 
disorder, psychopharmacological treatment, illicit drug use, and alcohol consumption. c Defined as stated by 
the National Institute on Drug Abuse (NIDA) from the National Institutes of Health (NIH). Club drugs are 
those that tend to be used in bars, nightclubs, concerts, and parties and include GHB, Rohypnol®, ketamine, 
MDMA (ecstasy), methamphetamine, and LSD (acid).
Early treatment (n = 12) Later treatment (n = 15) Control (n = 15) p value
Age, years 34 (10) 31 (9) 32 (10) 0.724
Male, n (%) 12 (100) 15 (100) 15 (100) –
Years of education 14 (2) 13 (2) 13 (3) 0.881
Estimated days since HIV-1 acquisition to cART 
initiation 63 (20) – – –
Days since HIV diagnosis to cART initiation 18 (12) 72 (80) – 0.028
cART naïve (%) 12 (100) 15 (100) – –
INSTI-based therapy initiated, n (%) 0.198
 TDF + FTC + RAL 4 (33) 1 (7) – –
 TDF/TAF + FTC + EVG 4 (33) 6 (40) – –
 ABC + 3TC + DTG 4 (33) 8 (53) – –
Plasma viral load  log10a 5.1 (0.97) 4.1 (0.88) – 0.010
CD4 cell count 537 (239) 475 (203) – 0.479
CD8 cell count 1025 (667) 1072 (839) – 0.877
CD4/CD8 ratio 0.64 (0.38) 0.53 (0.18) – 0.350
Contributing  comorbiditiesb, n (%) 6 (50) 5 (33) 5 (33) 0.604
Illicit drug use (last month), n (%) 6 (50) 5 (33) 4 (27) 0.441
 Marijuana 5 (42) 4 (27) 2 (13) 0.250
 Club  drugsc 2 (17) 3 (20) 2 (13) 0. 887
Figure 1.  Baseline and progression of NPZ-12. (A) Baseline NPZ-12 scores. Horizontal bars represent the 
mean. The statistical test applied was ANOVA for means. (B) Mean NPZ-12 scores. The p values shown above 
indicate early treatment vs control comparisons. The p values shown below indicate later treatment vs control 
comparisons. The statistical test applied was ANOVA for means.
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the early treatment arm compared with the control arm, with similar emotional status in both groups: depres-
sive, –3.55 (2.58) vs –0.60 (1.43), p = 0.005, d = –1.34; anxiety, –5.18 (3.46) vs –1.30 (2.49), p = 0.009, d = –1.23; 
perceived stress, –7.55 (3.88) vs 1.40 (4.72), p < 0.001, d = –2. In the later treatment arm, symptoms of stress had 
improved at week 48: –6.50 (9.24) vs 1.40 (4.72), p = 0.024, d = –1.01. Figures 2A–C summarize the progression 
of depressive, anxiety, and stress symptoms respectively. 
Brain imaging outcomes. No differences across the study groups were found in the baseline structural 
brain imaging assessments (p = 0.449).
Exploratory longitudinal voxel-wise analyses showed that gray matter had decreased significantly more in 
the later treatment arm than in the early treatment arm at week 4, specifically in the medial orbitofrontal cortex 
(p[FWE] = 0.030) (Fig. 3A).
There was no significant difference between the 3 groups at week 48. Longitudinal intra-group progression 
of gray matter volume revealed a statistically significant decrease in the medial orbitofrontal cortex across the 
timepoints in the later treatment arm (p = 0.001), which was not observed in the early treatment arm (p = 0.101) 
or the control arm (p = 0.064) (Fig. 3B).
Discussion
We did not observe significant differences in the cognitive status of men who had recently acquired HIV-1 
infection (< 3 months), men whose estimated time since HIV-1 acquisition was longer than 6 months, or men 
without HIV infection in this small prospective observational trial. The presence of HAND is well established 
and accepted in  PLWH14. However, the stage of infection when disorders first manifest is not well identified. 
Our data indicate that cognitive changes may be subtle during the initial stages of HIV-1 infection and that the 
Table 2.  Change in cognitive and functional outcomes. Values are expressed as mean (standard deviation). 
For global neurocognitive performance (NPZ-12) and quality of life, higher change scores represent 
improvement. For CNS adverse events, daily functioning, emotional status, and stress, lower change scores 
represent improvement. The treatment and control arms were compared using the independent t test. 
Statistical significance was set at p < 0.05. Bold values denote statistical significance. d size was obtained using 
Cohen’s d. Values are considered small when < 0.20, medium when ≥ 0.50 and ≤ 0.80, and large when > 0.80. 
Abbreviations: CNS = central nervous system. a Comparison between early treatment and control arms. 
b Comparison between later treatment and control arms.
Change from 
baseline
Early treatment (n = 12) Later treatment (n = 15) Control (n = 15)









Week 4 12 0.06 (0.20) 15 0.14 (0.25) 14 0.11 (0.28) 0.602; 0.789 −0.24; 0.07
Week 48 11 0.08 (0.26) 15 0.31 (0.28) 10 0.25 (0.19) 0.117; 0.538 −0.17; 0.25
CNS adverse events
Total
Week 4 12 0.83 (6.38) 14 −0.35 (5.87) 14 −0.57 (5.82) 0.563; 0.924 0.22; −0.04
Week 48 11 −2.90 (8.76) 12 0.33 (7.58) 10 0.30 (5.77) 0.340; 0.991 −0,41; −0.00
Daily functioning
Total impaired areas
Week 4 12 1.25 (1.65) 14 −0.28 (1.26) 14 0 (1.30) 0.047; 0.561 0.82; −0.21
Week 48 11 0.54 (1.69) 12 0.33 (2.01) 10 0.30 (0.82) 0.683; 0.962 0.17; 0.02
Emotional status
Depressive symptoms
Week 4 12 −0.67 (2.80) 14 −1.50 (3.15) 14 −0.71 (1.68) 0.960; 0.419 0.02; −0.30
Week 48 11 −3.55 (2.58) 12 −0.50 (3.84) 10 −0.60 (1.43) 0.005; 0.935 −1.34; 0.03
Anxiety symptoms
Week 4 12 −1.83 (3.97) 14 −1.43 (2.44) 14 −0.57 (1.55) 0.319; 0.278 −0.42; −0.41
Week 48 11 −5.18 (3.46) 12 −2.00 (2.93) 10 −1.30 (2.49) 0.009; 0.557 −1.23; −0.25
Perceived stress
Week 4 12 0.50 (8.36) 14 −5.36 (9.14) 14 −0.71 (3.95) 0.632; 0.093 0.18; −0.64
Week 48 11 −7.55 (3.88) 12 −6.50 (9.24) 10 1.40 (4.72) 0.001; 0.024 −2.0; −1.01
Quality of life
Global dimension
Week 4 12 −0.16 (0.71) 14 0.07 (0.47) 14 0.07 (0.61) 0.815; 1 −0.34; 0.00
Week 48 11 0.18 (0.40) 12 0.08 (0.51) 10 0.10 (0.73) 0.753; 0.953 0.15; −0.03
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neurobiological mechanisms underlying disruption of the CNS may not have developed sufficiently for cognitive 
disorders to manifest, as other investigators have  suggested25–27. The correlation found between worse neuropsy-
chological performance (NPZ-12 score) and longer time from diagnosis of HIV-1 infection would also support 
this hypothesis. In addition, the mean age of the study sample was not very high, and immunological param-
eters were mostly preserved. Also relevant is the fact that we did not detect significant cognitive improvement 
after 48 weeks of cART with INSTI, when both treatment groups were compared with untreated seronegative 
individuals. This effect could reasonably be anticipated due to the absence of baseline cognitive impairment in 
the HIV arms. In most studies that report cognitive improvement linked to initiation of cART, individuals had 
marked impairment before therapy was  started28. Another explanation for not finding cognitive changes over 
time is the limited period covered in the follow-up study (12 months). It is also important to note that the most 
extensively used criteria to categorize cognitive impairment in HIV infection, the Frascati criteria, have been 
called into question owing to the potential for  misclassification29,30. Cerebrospinal fluid analyses could have 
provided additional information about slight improvements in inflammatory or neurological biomarkers, thus 
complementing subtle cognitive changes not captured by neuropsychological assessments. However, unfortu-
nately, analysis of cerebrospinal fluid was not included in the methodology of our study.
Figure 2.  Progression of depressive, anxiety, and stress symptoms. The p values shown above indicate early 
treatment vs control comparisons. The p values shown below indicate later treatment vs control comparisons. 
The statistical test applied was ANOVA for means. Bold p values denote statistical significance. (A) Mean 
depression scores. Bars represent the standard error of the mean. (B) Mean anxiety scores. Bars represent the 
standard error of the mean. (C) Mean stress scores. Bars represent the standard error of the mean.
Figure 3.  Medial orbitofrontal cortex and mean volume values. (A) Voxels showing a significantly larger 
decrease in gray matter volume at week 4 in relation to baseline in the later treatment arm than in the early 
treatment arm. These voxels were located at the medial orbitofrontal cortex, with the most significant finding 
(peak coordinate) at x = 6; y = 44; z = –32 (T = 4.46; p(FWE) = 0.030). (B) Mean medial orbitofrontal cortex scores 
found prospectively. Upper bars represent the standard error of the mean. The Y axis is disproportionate to 
provide a more optimal presentation of outcomes. The statistical test applied was the longitudinal ANOVA for 
repeated measures. Bold p value denotes statistical significance. Abbreviations: OFC = orbitofrontal cortex.
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One of the strengths of this trial was that it assessed a variable range of functional measures. Such an approach 
is very unusual. In fact, in people with early infection we reveal significantly worse emotional status, which is 
not found in PLWH who initiate treatment later. We detected symptoms at 3 levels: depressive, anxiety, and per-
ceived stress. Consistent with our data, other studies have reported high rates of depressive symptoms in people 
with recent/acute HIV-1  infection31,32. This finding could reasonably be explained as the initial psychological 
impact of a recent diagnosis of HIV infection. Alternatively, some authors have pointed out that these altera-
tions could be related to the immune activation that manifests during acute/primary  infection32. Importantly, 
we found that these symptoms resolved after 48 weeks on therapy. The improvement in emotional status could 
be associated with the process of emotionally adapting to the infection, or as a result of using cART. In any case, 
INSTI-containing therapy appeared not to have a negative impact on emotional status.
Another interesting aspect of our work was the inclusion of structural brain imaging in the study analyses. 
This methodology has previously been used in the field, with proven sensitivity for detection of subtle anatomi-
cal brain changes associated with HIV  infection33. Brain imaging did not reveal differences in brain imaging 
outcomes between the groups at baseline. Again, this could be explained by the short duration of the infection 
in both HIV groups. Most of the studies revealing subcortical and cortical atrophy in PLWH covered longer 
times with HIV  infection34–37. Of note, when we analyzed structural outcomes longitudinally, we found a greater 
decrease in the gray matter of the medial orbitofrontal area in the participants who started therapy later. Previous 
cross-sectional investigations report reductions in the gray matter of the orbitofrontal cortex in PLWH compared 
with non-PLWH individuals, thus supporting our  finding34,38. The results we report were prospective and appear 
to capture the initial stage of onset of these structural changes. Indeed, the orbitofrontal area seems to be suscepti-
ble to damage caused by HIV. This area is known to play a role in adaptive and objective behavior and is associated 
with decision-making  processes39. Longitudinal neuroimaging studies investigating healthy aging support that 
a certain loss of gray matter is normal over  time40. Consistent with this observation, we found a trend towards 
reduced medial orbitofrontal cortex in all groups, although the differences were only statistically significant in 
individuals who began cART later. While INSTI have been reported to induce neurotoxicity through several 
molecular mechanisms in in vitro studies, such as altering lysosomal function leading to  neuroinflammation41 
or hyperexcitability of medial prefrontal cortex pyramidal  neurons42, our data show that the longer-term effect 
of HIV-1 itself in the brain could be more harmful than potential INSTI-related neurotoxicity, at least to the 
extent that neuroimaging can reveal clinically significant findings.
Our study was subject to limitations. First, the sample size was small, and data from a reduced group of par-
ticipants were not included in the prospective analyses because of the exclusion criteria. In addition, the sample 
only included MLWH, thus limiting the generalizability of the results to PLWH. In fact, different outcomes might 
be found in women living with HIV, in part due to anatomical differences in brain structure or other potential 
sex-related confounders. Second, we recorded a fairly high rate of illicit drug use, which could affect brain-related 
outcomes. Third, the results are mostly representative of the INSTI studied and may not therefore be applicable 
to other currently used agents in clinical practice (e.g., bictegravir or cabotegravir). Finally, cerebrospinal fluid 
was not evaluated. Data on this analytical parameter may have been able to explain outcomes connected with 
cognitive and brain imaging findings. The main reason for not including these evaluations was the intention not 
to enlarge the assessment burden for study participants, since evaluations were already very comprehensive. The 
fact that participants were assessed at 3 points also prevented this parameter from being used.
Summary and conclusion
According to our findings, changes in CNS functioning in early stages of HIV infection appear to be subtle and do 
not seem to substantially affect cognition. However, functional status is already affected during the first 3 months 
after infection, and early initiation of cART with INSTI is beneficial for emotional status in particular. Regard-
ing brain imaging status, we report that MLWH initiating cART later may experience a more marked decrease 
in medial orbitofrontal cortex volume over time, with likely negative repercussions for decision-making tasks.
Data availability
All study data are available from Fundació Lluita contra la SIDA (www. flsida. org) in line with local data protec-
tion laws. Anonymized data can be shared for academic and scientific purposes, always following required ethical 
procedures. Requests can be made by contacting the corresponding authors.
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